tradingkey.logo
tradingkey.logo
Search

MoonLake Immunotherapeutics

MLTX
Add to Watchlist
18.440USD
-0.550-2.90%
Close 07-31 16:00ETQuotes delayed by 15 min
1.52BMarket Cap
LossP/E TTM

MoonLake Immunotherapeutics

18.440
-0.550-2.90%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.90%

5 Days

-3.05%

1 Month

-2.69%

6 Months

+16.78%

Year to Date

+39.91%

1 Year

-65.15%

Key Figures
18.940Open
18.960High
791.76KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.10%Turnover Ratio
18.990Prev. Close
18.370Low
10.45MTurnover
LossP/E Static
5.24P/B
0.00%Div Yield TTM
-56.92%ROA
62.75052wk High
0.96Volume Ratio
-118.94MNet Profit
72.13MShares
-3.8726EPS TTM
1.02Beta
-77.72%ROE
5.95052wk Low
3.11%Amplitude
--Gross Margin
1.52BMarket Cap
0.14Reward/Risk
4.07%Risk Rate

MoonLake Immunotherapeutics News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 16 analysts
Buy
Current Rating
31.000
Target Price
+68.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
MoonLake Immunotherapeutics
MLTX
16
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.298
Neutral
RSI(14)
45.248
Neutral
STOCH(KDJ)(9,3,3)
17.041
Neutral
ATR(14)
1.014
Low Volatility
CCI(14)
-131.925
Sell
Williams %R
93.966
Oversold
TRIX(12,20)
-0.073
Sell
StochRSI(14)
9.404
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
18.880
Sell
MA10
19.083
Sell
MA20
19.340
Sell
MA50
19.072
Sell
MA100
18.240
Buy
MA200
16.170
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

MoonLake Immunotherapeutics Info

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Ticker SymbolMLTX
CompanyMoonLake Immunotherapeutics
CEOSantos Da Silva (Jorge)
Websitehttps://moonlaketx.com/

Shareholders

Shareholders
Shareholders
Proportion
BVF Partners L.P.
21.74%
Deep Track Capital LP
6.26%
Cormorant Asset Management, LP
5.92%
Reich (Kristian)
4.09%
Santos da Silva (Jorge)
4.01%
Other
57.98%

FAQs

What is the current price of MoonLake Immunotherapeutics (MLTX)?

The current price of MoonLake Immunotherapeutics (MLTX) is 18.44.

What is the symbol of MoonLake Immunotherapeutics?

The ticker symbol of MoonLake Immunotherapeutics is MLTX.

What is the 52-week high of MoonLake Immunotherapeutics?

The 52-week high of MoonLake Immunotherapeutics is 62.75.

What is the 52-week low of MoonLake Immunotherapeutics?

The 52-week low of MoonLake Immunotherapeutics is 5.95.

What is the market capitalization of MoonLake Immunotherapeutics?

The market capitalization of MoonLake Immunotherapeutics is 1.52B.

Is MoonLake Immunotherapeutics (MLTX) currently rated as Buy, Hold, or Sell?

According to analysts, MoonLake Immunotherapeutics (MLTX) has an overall rating of Buy, with a price target of 31.00.

What is the Earnings Per Share (EPS TTM) of MoonLake Immunotherapeutics (MLTX)?

The Earnings Per Share (EPS TTM) of MoonLake Immunotherapeutics (MLTX) is -3.53.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.